Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective, Multicentre, Nationwide Clinical Data from 600 Cases of Acute Pancreatitis.
Párniczky A, Kui B, Szentesi A, Balázs A, Szűcs Á, Mosztbacher D, Czimmer J, Sarlós P, Bajor J, Gódi S, Vincze Á, Illés A, Szabó I, Pár G, Takács T, Czakó L, Szepes Z, Rakonczay Z, Izbéki F, Gervain J, Halász A, Novák J, Crai S, Hritz I, Góg C, Sümegi J, Golovics P, Varga M, Bod B, Hamvas J, Varga-Müller M, Papp Z, Sahin-Tóth M, Hegyi P; Hungarian Pancreatic Study Group. Párniczky A, et al. Among authors: golovics p. PLoS One. 2016 Oct 31;11(10):e0165309. doi: 10.1371/journal.pone.0165309. eCollection 2016. PLoS One. 2016. PMID: 27798670 Free PMC article.
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Kristóf T, Lakatos L, Csontos ÁA, Juhász M, Nagy F, Palatka K, Papp M, Patai Á, Lakner L, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Szalay B, Molnár T, Lakatos PL. Gecse KB, et al. J Crohns Colitis. 2016 Feb;10(2):133-40. doi: 10.1093/ecco-jcc/jjv220. Epub 2015 Dec 10. J Crohns Colitis. 2016. PMID: 26661272 Clinical Trial.
Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?
Gonczi L, Vegh Z, Golovics PA, Rutka M, Gecse KB, Bor R, Farkas K, Szamosi T, Bene L, Gasztonyi B, Kristóf T, Lakatos L, Miheller P, Palatka K, Papp M, Patai Á, Salamon Á, Tóth GT, Vincze Á, Biro E, Lovasz BD, Kurti Z, Szepes Z, Molnár T, Lakatos PL. Gonczi L, et al. Among authors: golovics pa. J Crohns Colitis. 2017 Jun 1;11(6):697-705. doi: 10.1093/ecco-jcc/jjw203. J Crohns Colitis. 2017. PMID: 27838610
Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort.
Gonczi L, Gecse KB, Vegh Z, Kurti Z, Rutka M, Farkas K, Golovics PA, Lovasz BD, Banai J, Bene L, Gasztonyi B, Kristof T, Lakatos L, Miheller P, Nagy F, Palatka K, Papp M, Patai A, Salamon A, Szamosi T, Szepes Z, Toth GT, Vincze A, Szalay B, Molnar T, Lakatos PL. Gonczi L, et al. Among authors: golovics pa. Inflamm Bowel Dis. 2017 Nov;23(11):1908-1915. doi: 10.1097/MIB.0000000000001237. Inflamm Bowel Dis. 2017. PMID: 28922253
Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - A prospective, multicenter cohort from Hungary.
Gonczi L, Szanto K, Farkas K, Molnar T, Szamosi T, Schafer E, Golovics PA, Barkai L, Lontai L, Lovasz B, Juhasz M, Patai A, Sarang K, Vincze A, Sarlos P, Farkas A, Dubravcsik Z, Toth TG, Miheller P, Ilias A, Lakatos PL. Gonczi L, et al. Among authors: golovics pa. Dig Liver Dis. 2022 Feb;54(2):207-213. doi: 10.1016/j.dld.2021.07.008. Epub 2021 Jul 31. Dig Liver Dis. 2022. PMID: 34344576
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL; Hungarian IBD Study Group. Kiss LS, et al. Among authors: golovics pa. Aliment Pharmacol Ther. 2011 Oct;34(8):911-22. doi: 10.1111/j.1365-2036.2011.04827.x. Epub 2011 Aug 24. Aliment Pharmacol Ther. 2011. PMID: 21883326 Free article.
Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K, Rutka M, Golovics PA, Végh Z, Lovász BD, Nyári T, Gecse KB, Kolar M, Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Malickova K, Bálint A, Nagy F, Bor R, Milassin Á, Szepes Z, Palatka K, Lakatos PL, Lukas M, Molnár T. Farkas K, et al. J Crohns Colitis. 2016 Nov;10(11):1273-1278. doi: 10.1093/ecco-jcc/jjw085. Epub 2016 Apr 21. J Crohns Colitis. 2016. PMID: 27106537 Clinical Trial.
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS, Szamosi T, Molnár T, Miheller P, Lakatos L, Vincze A, Palatka K, Bartha Z, Gasztonyi B, Salamon A, Horváth G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovász BD, Végh Z, Golovics PA, Szathmári M, Papp M, Lakatos PL. Kiss LS, et al. Among authors: golovics pa. Orv Hetil. 2011 Sep 4;152(36):1433-42. doi: 10.1556/OH.2011.29200. Orv Hetil. 2011. PMID: 21865144 Hungarian.
67 results